



なにげない感動をずっと。

FANCL

Development of Anti-Aging Materials (Koji Mold and *Agrimonia pilosa* Ledeb.)

KIRIN R&D DAY 2025
Kirin Holdings Co., Ltd. Health Science
Research Institute

KIRIN R&D DAY 2025
FANCL Corporation
Functional Food Research Institute

Yoshihiko Sugihara

Mariko Hayashida

Anti-Aging Research by FANCL and Kirin

KIRIN
Koji sterols



FANCL
Agrimonia pilosa Ledeb.

Cell.2023 Jan 19;186(2):243-278.

Discover ingredients through proprietary approaches

From Encounter with *A. pilosa* Ledeb. to Anti-Aging Research


After identifying the cognitive function-improving effects of *A. Pilosa* Ledeb., we subsequently identified its senolytic activity.

Screening for cognitive function-improving materials using a library of **4,000 candidates.**



Confirmation of the neuroactivating effect by *A. pilosa* Ledeb.

Identification of Active Compound



Confirmed multiple anti-aging effects

2015

2020

2025

Confirmed Vigor and Activity Enhancement via *A. pilosa* Extract Intake.

Confirmation of Senolytic Effect *in vitro*.

Establishment of the evaluation method for senescent cells in humans.

Global Growth of Geroscience Research
Research funding continues to rise
Demographic aging is certain to continue
Advances in Aging Research Contribute to Social Well-Being


An economic analysis suggests that slowing aging to increase life expectancy by 1 year is worth **US\$38 trillion**

Nat Aging. 2021 Jul;1(7):616-623.

XPRIZE Healthspan Launched
(A global competition aiming to extend healthy life expectancy)

Senolytic effect of *Agrimonia pilosa* extract *in vitro*

Treatment with *A. pilosa* extract reduced senescent cells in a dose-dependent manner.





Human verification essential for commercialization

Overview of Technology for Evaluation of Human Senescent Cells

Challenge: No rapid, minimally invasive, high-throughput quantification of human senescent cells.

➔ Quantify senescent cells using blood cells obtained via minimally invasive sampling.






From the presentation materials of the 20th CCVAA Annual Meeting.
[Study Design] Cross-sectional study
[Subjects] 107 men and women aged 20 to 69 years (55 women, 52 men)
[Outcomes] % SA-βGal^{high} CD8⁺ T cells in PBMCs

Clinical study: Effects of *Agrimonia pilosa* Extract on Vigor and Activity

Trial Design	Randomized placebo-controlled double-blind parallel-group comparative trial
Participants	<ul style="list-style-type: none"> •84 healthy adult men and women aged 40 to 60 •Participants with a T-score for the vigor-activity (VA) scale of 50 or lower and a T-score for the fatigue-inertia (FI) scale of 50 or higher on the POMS 2-A short.
Test food	<i>Agrimonia pilosa</i> extract 50 mg/day (0.2 mg of agrimols derived from <i>Agrimonia pilosa</i> L) or placebo
Intervention period	12 weeks
Evaluation Criteria	Primary Outcome: POMS2 Secondary Outcomes: SF-36v2, Apathy Scale, Anti-Aging QOL Common Questionnaire, SCD-Q



Jpn Pharmacol Ther.2024;52(7):775-789.